C-WDDPEtheros Pharmaceuticals
enzyme mimetics, neuroprotection, healthspan
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-WDDP
C-WDDPC-WDDPenzyme mimetics, neuroprotection, healthspan
0-100 chain-logic scale · 15 dimensions · scored on public evidence
true The Company is filing this Current Report on Form 8-K/A to amend the Original Filing to provide unaudited condensed financial statements of LNHC as of June 30, 2025 and 2024 and for the three and six months ended June 30, 2025 and June 30, 2024 and the pro forma financial information required by Item 9.01(b) of Form 8-K in connection with the Merger. 0001919246 0001919246 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM 8-K/A (Amendment No. 1)   CURRENT REPORT  … owned subsidiary of Ligand.   In January 2023, Novan submitted a New Drug Application to the U.S. Food and Drug Administration (the “FDA”) for berdazimer gel, 10.3% as a topical treatment for molluscum contagiosum. ZELSUVMI (berdazimer) topical gel, 10.3%, was approved by the FDA on January 5, 2024.   ZELSUVMI is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients 1 year of ag … al treatments administered in medical settings such as cryosurgery, cantharidin application and curettage.   Proprietary NITRICIL™ Technology Platform Overview   The NITRICIL proprietary technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory potential mechanisms of action in an effort to treat a range of diseases. Nitric oxide plays a vital role in the natural immune system response … “PTE”) for the U.S. patent covering ZELSUVMI compositions. Assuming grant of the PTE application, the term of this patent may be extended from February 27, 2034, to August 30, 2037.   Other Patent Data   Patent Term   Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries, in which they are obtained. Generally, utility paten … exceed 14 years following FDA approval of the drug, and the extension may only apply to one patent that covers the approved drug (and to only those patent claims covering the approved drug or a method for using it). There can be no assurance that any such patent term adjustment or extension will be obtained. The duration of foreign patents varie
User | times-online.com - Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants Skip to main content Sign Up Log In Dashboard Logout My Account Dashboard Profile Saved items Logout Home News Local News Sports Obituaries e-Edition Classifieds Real Estate Property For Rent Cars & Vehicles Jobs Items For Sale Pets Auctions, Estate & Garage Sales Services Community Personals Place An Ad Explore the Sheyenne Archives Best of 2025 Subscribe Site search Search Contact Us Subscribe e-Edition Sign Up Log In Dashboard Logout My Account D … ecember 10, 2025 -- Immortal Dragons , the $40 million purpose-driven longevity fund, today announced its strategic investment in Etheros Pharmaceuticals, a biotechnology company developing a new class of drugs to combat diseases of aging and which may slow human aging itself. Etheros is focused on advancing water-soluble fullerene derivatives that act as catalytic antioxidants, designed to neutralize the oxidative stress implicated in cellular damage and age-related conditio … scovery of the C60 carbon sphere, an achievement recognized with the 1996 Nobel Prize in Chemistry. While C60 is insoluble in water, Etheros has developed proprietary water-soluble derivatives for potential therapeutic use. These compounds possess a unique chemistry that allows them to function as mimics of the body’s antioxidant enzymes, primarily superoxide dismutase (SOD). Unlike conventional antioxidants that are typically consumed in the process of neutralizing ROS, Ethe … chnology. About Immortal Dragons Immortal Dragons is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders’ talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to long
Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Pontiro Exhibits at GIANT Health 2025, Enhancing Medical Imaging Data Security | GIANT Health Event posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue
Etheros Investor Portal Portfolio Events Insights Ethos Team Menu Menu Close Investor Portal Portfolio Events Insights Ethos Team X LinkedIn Instagram YouTube UK Healthtech Etheros Year Backed: 2023 Stage: Seed Website Careers Etheros is developing a new class of small molecule drugs that mimic endogenous enzymes to prevent oxidative and inflammatory injury, particularly in neural tissue. Their lead compound has demonstrated neuroprotective effects in placebo-controlled animal studies and extends median lifespan in wild-type mice, offering transformative potential for neuroprotection and healt
Etheros - Fullerene Chemistry for Longevity | VitaDAO WHY LONGEVITY RESEARCH VITA LABS VITA TOKEN PROJECTS BLOG STORE GET VITA LOADING EQUITY A VITADAO PROJECT Etheros - Fullerene Chemistry for Longevity ageing neuro protection fullerene chemistry EQUITY Funding $50,000 Initiated 05.04.2023 Dr Jack Scannell CEO Dr Subhasish Chakraborty Founder Frank Kneutell COO / CFO Professor Laura Dugan Founder and Director Professor Sir Marc Feldman Founder AT A GLANCE Stage : Preclinical development PROJECT LINKS View governance proposal View on-chain vote Funding $50,000 Initiated 05.04.2023 Dr Jack Sc … under AT A GLANCE Stage : Preclinical development PROJECT LINKS View governance proposal View on-chain vote Etheros is developing a new class of small molecule drugs based on fullerene chemistry. The lead compound has shown to extend mouse lifespan, improve cognition in elderly mice, and has been neuroprotective in various animal studies. The compounds mimic enzymes that protect cells from oxidative and inflammatory injury. The current raise will help Etheros improve its IP … a biotech company pioneering a new class of small molecule drugs based on Nobel Prize-winning fullerene chemistry. Their lead compound, which mimics enzymes called superoxide dismutases that protect cells from oxidative and inflammatory injury, has already shown promise in animal studies for a wide range of diseases, including Parkinson's Disease, familial ALS, and asphyxia-induced brain injury. Etheros believes their compounds' novel catalytic activity makes them more potent … ons and proving the therapeutic concept before raising the capital necessary to fund trials in more common diseases. Aims, Hypothesis & Results The aim of the Etheros project is to develop a new class of small molecule drugs based on Nobel Prize-winning fullerene chemistry that mimic enzymes called superoxide dismutases. These enzymes protect cells from oxidative and inflammatory injury, which neuronal tissue is particularly sensitive to. The hypothesis is that these comp … stry with CoM patent. The company is currently focused on developing a clinical application for rare disease and military application in the short term. In the medium term, the company plans to develop a clinical application for PD with novel chemistry with CoM patent. In the long term, the company plans to develop a clinical application for AD,
Etheros Pharmaceuticals Corp. - fund raising filing FormDs.com Newest Filter Local Etheros Pharmaceuticals Corp. Industry: Pharmaceuticals (See others in industry) Address: 111 10 Th Ave S Ste 110 Nashville, TN, 37203 Phone: 615-212-9695 Filings Date Filing Type Reported Sold Incremental Cash Type Exemptions Link to Raw Filing 2025-06-10 New $600,000 $600,000 Other 06b SEC link 2023-12-20 New $775,000 $775,000 Other 06b SEC link 2023-12-20 New $300,000 $300,000 Other 06b SEC link Directors and Executives (Current and Past) Name Role Subhasish Chakraborty Executive Laura Dugan Director Marc Fel
All Dr Jack Scannell (CEO of Etheros Pharmaceuticals Corp) articles | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques B
We were delighted to be asked... - Celebration Balloons 4 You Facebook Log In Celebration Balloons 4 You's Post
Healthcare Private Placement and M&A Transactions Review Week Ending December 14, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending D … es, NewHealth Ventures, Osage Venture Partners, Shoni Health Ventures and aMoon Fund also participated in the round. The company is a developer of a digital, integrated behavioral health therapy platform designed to offer diagnosis and treatment for people suffering from chronic pain. uMethod: The company raised $4.5 million of venture funding in the form of convertible debt from undisclosed investors on December 8, 2025. The company is a provider of evidence-based, personali
NWA Live Music Events | MOREPROTOBLIVIATEMAN | Hero's Fort Smith Obliviate, More Weight, The Salesman, Protohive
Etheros Pharmaceuticals Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors &
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
#digitalhealth #healthcareinnovation #pharmainnovation #ubiqevents | UBIQ events LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User
Beyond Biotech podcast 60 – The cost of research Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector App
You need to enable JavaScript to run this app. Loading...
The predictive validity crisis: Pharma’s productivity paradox – Part II | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools an … often reflects the same problems plaguing model selection. Companies frequently apply sophisticated algorithms to fundamentally flawed datasets, creating an illusion of progress while reinforcing existing limitations. The focus shifts to coding efficiency and mathematical sophistication at the expense of data quality and biological relevance. True algorithmic innovation in drug discovery requires aligning computational approaches with problems where the underlying biology is
Form D FORM D Notice of Exempt Offering of Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. OMB APPROVAL OMB Number: 3235-0076 Estimated Average burden hours per response: 4.0 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) None Entity Type 0002005132 Corporation Limited Partnership Limited Liability Company General Partnership Business Trust Other Name of Issuer Etheros Pharmaceuticals Corp. Jurisdiction of Incorporation/Organization DELAWARE Year of Incorporation/Organization Over Five Years Ago Within Last Five Years (Specify Year) 2022 Yet to Be Form … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate Retailing Restaurants Tech … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 506(b) Rule 504 (b)(1)(i) Rule 506(c) Rule 504 (b)(1)(ii) Securities Act Section 4(a)(5) Rule 504 (b)(1)(iii) Investment Company Act Section 3(c) 7. Type of Filing New Notice Date of First Sale 2025-01-31 First Sale Yet to Occur Amendment 8. Duration of Offering Does the Issuer intend this offering to last more than one year? Yes No 9. Type(s) of … st more than one year? Yes No 9. Type(s) of Securities Offered (select all that apply) Pooled Investment Fund Interests Equity Tenant-in-Common Securities Debt Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) Simple agreement for future equity (SAFE) 10. Business Combination Transaction Is this offering being made in connection wit … ve entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice. Terms of Submission In submitting this notice, each Issuer named above is: Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request
pths-20251231 FALSE FY 2025 0001919246 0.1 0.01 123 0.11 0.1 iso4217:USD xbrli:shares iso4217:USD xbrli:shares pths:product xbrli:pure pths:investor pths:lender pths:agreement pths:batch pths:segment pths:contingentMilestone pths:netSaleAchievment pths:tradingDay pths:consecutiveTradingDay pths:instrument utr:Y pths:patent utr:sqft pths:option pths:assetAcquisition pths:acquiredProduct 0001919246 2025-01-01 2025-12-31 0001919246 2025-06-30 0001919246 2026-03-11 0001919246 2025-10-01 2025-12-31 0001919246 2025-12-31 0001919246 2024-12-31 0001919246 us-gaap:NonrelatedPartyMember 2025-12-31 00019 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” … al treatments administered in medical settings such as cryosurgery, cantharidin application and curettage. The Company has an exclusive license to use the NITRICIL Technology Platform as necessary to manufacture ZELSUVMI, as set forth in the license agreement between the Company and Ligand. The Company believes that the NITRICIL platform’s ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows the potential to improve patient outc … ocesses critical to egg development and survival of lice. The single, 10 minute application does not require nit combing and has sufficient volume in each bottle to treat either short or long hair. 7 The Company expects to commercially launch XEGLYZE once certain manufacturing, supply chain, and regulatory activities are validated, implemented and completed, respectively. In addition, the Company will also need to implement its commercial marketing, trade and access strategy … icacy studies and has successfully completed a pivotal Investigational New Drug Application (“IND”) enabling ophthalmic toxicology studies as a precursor to launching a Phase 1a/2b human proof of concept study. The Company expects to initiate the Phase 1a/2b study in Eye Pain in the first quarter of 2026. Depot Program (Pre-Clinical)
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Our Team – etherospharma.com Skip to main content Hit enter to search or ESC to close Close Search Menu Home Our Science Our Team Contact Our Team Etheros founders Professor Sir Marc Feldmann Chairman is an immunologist who discovered and pioneered the anti-TNFs, the World’s best selling drug class. He is a winner of the Lasker Award and former Director of the Kennedy Institute at Oxford University. He has founded several biotech firms. Professor Laura Dugan Scientific Lead is a clinician and scientist who pioneered the Etheros technology at University of California, Wash U, and now at V
The Needle Issue #21 Haystack Science Open menu Posts The Needle Issue #21 Published 6 months ago • 15 min read ISSUE 21 Welcome to The Needle, a newsletter from Haystack Science to help you navigate the latest translational research, with a roundup of the latest news on preclinical biotech startups from around the world. It has been a busy few weeks for rare disease news, culminating with the FDA’s first approval for a treatment sponsored by a non-profit foundation . In terms of translational research a bumper crop of companies announced research breakthroughs, including Enterprise Therapeuti … ed by the US Department of Health and Human Services (HHS), 585 advocacy groups fund “medical product development” activities in the United States. Why has it taken an Italian non-profit organization to be the first to cross the US FDA approval finish line? The organization responsible for development of Waskyra is the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), a 30-year-old partnership between Telethon Foundation and Milan’s Ospedale San Raffaele. Over thos … e with their own research staff and lab space. In contrast, 106 advocacy groups fund life-science companies, and 536 fund academic or medical institutions. This implies that, at most, only 1.9% of US patient groups use a model that shares at least some similarities with SR-TIGET’s. This is important to emphasize because having all these in-house capabilities makes an organization less dependent on industry partnerships, which can be difficult to secure in the first place and … strategy. Mean (blue) and median (red) revenue of patient advocacy groups that fund medical research. As the categories are not mutually exclusive, individual organizations may be included in multiple categories. Source: Lee, KM et al., May 2025 It is worthwhile noting that Waskyra is not Fondazione Telethon’s first rodeo. SR-TIGET was responsible for much of the work behind two other approved ex vivo lentiviral gene therapies for ultrarare conditions: Strimvelis (for ADA- … s with its platform for ultra-rare conditions (recently receiving an $8 million grant from the Center for Regenerative Medicines) Again, Elpida is focusing on just one modality and developing it against multiple neurodevelopmental and neurodegenerative conditions: Charcot-Marie-Tooth disease type 4J , Spastic Paraplegia 50 (SPG50) , and Neuronal
%PDF-1.7 %���� 1 0 obj >/Metadata 2492 0 R/ViewerPreferences 2493 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��Wmo�H����O'�j���7)�HR�kN��� �~p��́����/;�k �ne�ggg��af�x��*�$i��>���p��s.��!�_sXf�ΗwPt;އ��U�#`�s���oxO�u;v;p�Q����s�?�~q�+�� Zq߆�Z }$'Y菬 x� ��4 m>o� �^VU�β1|�zeU��o�h�ȼ�d�I���7\�Wd�)�*[>�����FR�� ��dh�x v;ף�J��� dJ�Vv(E�b��b��N�:�p��X���Sp�����})C� �f!1�8 �fUK�K�*'��a�)>���'UM�B �|&��\����
%PDF-1.4 %���� 1 0 obj >/OutputIntents[ >] /Metadata 669 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.96 840.96] /Contents 4 0 R/StructParents 0>> endobj 4 0 obj > stream x��Z[k 7~7�?��D�H] �K� �65���!'i��6u��ݝ=�9������J�O3�o$��'?��O��~q�R�g���/�_�gFm�q!)�^砒7�������G�6�`����{�D�3*����G�g?���W�_(%�A��:�huB�,�uK��5TE �#+PW�5�����P��'�U�H&u���Yᓎ$��M�";�������P&�T[���1&,#8�8�M�aŊ�+b�K ��K$ ��Y����Hԥ)xb19�U���$s4�L�C 됎qGr�_*��I�q�B���,0,��� @�Y{�� �.�4ɥ�s�� ��������Hz/� ����h��H袈h���" 9�@�D���"g"�Ls
Etheros HealthData Foundation Skip to content HOME DONATE RESEARCH CONTACT US Menu HOME DONATE RESEARCH CONTACT US Personal Health Data Ownership for a Healthier Tomorrow CONTACT US EMPOWERING INDIVIDUALS TO OWN, SHARE, AND BENEFIT FROM THEIR HEALTH DATA Our Mission Etheros HealthData Foundation (EHF) is a nonprofit organization dedicated to revolutionizing health data management by empowering individuals to own, share, and derive benefits from their health data. We envision a world where individual empowerment in healthcare data ownership transcends borders, laying the groundwork for an inclu
March 19, 2026 - 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | Pelthos Therapeutics Inc. (PTHS) March 19, 2026 > Form 10-K > Pelthos Therapeutics Inc. Document Links Form: 10-K Annual report [Section 13 and 15(d), not S-K Item 405] March 19, 2026 Complete Filing PDF » Includes filing and all documents Documents 10-K » EX-21.1 » EX-23.1 » EX-23.2 » EX-31.1 » EX-31.2 » EX-32.1 » EX-32.2 » EX-99.1 » 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] Pu … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer … al treatments administered in medical settings such as cryosurgery, cantharidin application and curettage. The Company has an exclusive license to use the NITRICIL Technology Platform as necessary to manufacture ZELSUVMI, as set forth in the license agreement between the Company and Ligand. The Company believes that the NITRICIL platform’s ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows the potential to improve patient outcomes i … ocesses critical to egg development and survival of lice. The single, 10 minute application does not require nit combing and has sufficient volume in each bottle to treat either short or long hair. 7 The Company expects to commercially launch XEGLYZE once certain manufacturing, supply chain, and regulatory activities are validated, implemented and completed, respectively. In addition, the Company will also need to implement its commercial marketing, trade and access strategy … icacy studies and has successfully completed a pivotal Investigational New Drug Application (“IND”) enabling ophthalmic toxicology studies as a precursor to launching a Phase 1a/2b human proof of concept study. The Company expects to initiate the Phase 1a/2b study in Eye Pain in the first quarter of 2026. Depot Program (Pre-Clinical) : Based on s
ETHEROS HEALTHDATA FOUNDATION CORP (EIN 93-4296924) - Grants, Funding, 990s Search Learn about Our Products Ecosystems Portfolios Due Diligence Funder Prospecting Log in Start for Free ETHEROS HEALTHDATA FOUNDATION CORP Sign up to claim this org ETHEROS HEALTHDATA FOUNDATION CORP Lexington, MA, US • 501(c)(3) • EIN 93-4296924 ETHEROS HEALTHDATA FOUNDATION CORP Sign up to claim this org Lexington, MA, US • 501(c)(3) • EIN 93-4296924 Overview Programs 990s Income Statement Balance Sheet Sign up for more: General Match Analysis People Board & Team Financials Financial Trends Funding Funders G … Lu Zheng Board Member Y Yi Zhang Board Member Frequently Asked Questions Can I submit an unsolicited grant proposal to ETHEROS HEALTHDATA FOUNDATION CORP ? No. ETHEROS HEALTHDATA FOUNDATION CORP does not accept unsolicited proposals. Funding is by invitation only. How do we apply to ETHEROS HEALTHDATA FOUNDATION CORP ? ETHEROS HEALTHDATA FOUNDATION CORP does not accept unsolicited proposals. Funding is by invitation only. Overview Copyright 2026. All rights reserved to Chari
etherospharma.com – Small molecule enzyme mimetics for neuroprotection and healthspan Skip to main content Hit enter to search or ESC to close Close Search Menu Home Our Science Our Team Contact Small molecule enzyme mimetics for neuroprotection and healthspan Etheros is pioneering a new class of small molecule drugs which mimic the endogenous enzymes, superoxide dismutase and catalase, that prevent oxidative and inflammatory injury; injury to which neural tissue is particularly sensitive. Our lead compound is neuroprotective in a diverse set of double-blind, placebo-controlled animal st
A New National Purpose: Leading the Biotech Revolution Skip to content NEWSLETTER Tony Blair Institute for Global Change WHAT WE DO WHAT WE DO APPROACH PARTNERSHIPS FUTURE OF BRITAIN INSIGHTS INSIGHTS EXPERTS EXPERTS WHO WE ARE WHO WE ARE ABOUT US EXECUTIVE LEADERSHIP CAREERS MENU Politics & Governance A New National Purpose: Leading the Biotech Revolution Paper 25th January 2024 By multiple experts (7) Contributors: Adam Bradshaw, Axel Heitmueller, Jeegar Kakkad, Anand Muthusamy, Ned Naylor, Charlotte Refsum, Eric Salem, Srinidhi Soundararajan A New National Purpose: Leading the Biotech R … biotech faces in the UK, but they feed into the broader theme of how strategic application of innovation and the right infrastructure can power a reimagined state in which people lead better, longer, safer lives. The common thread throughout this report is a question: building on Britain’s existing strengths, what does “reimagining the state” look like for biotechnology and the opportunity it presents? The report’s recommendations answer that question in a variety of ways, i … esearch laboratory with a well-resourced core institute that has the ability to fund researchers and clinicians around the country. These will complement and assist, not replace, human doctors. The acquisition of quality human data is a global bottleneck for AI, but the UK Biobank and the establishment of an NHS Data Trust, proposed below, would together offer a competitive edge. A new NHS Data Trust (NHSDT) to capitalise on the opportunities of health data. Owned and control … uncil-Department for Science, Innovation and Technology metascience unit should fund the development of methodology to assess talent flows of the most globally sought-after researchers, rather than rely on bulk numbers alone, as is conventional. [_] For example, this effort should identify the extent to which graduates of the world’s leading synthetic-biology labs, who understand the cutting edge, move to the UK. Such research should also seek to engage 1:1 with first-rate in … ive bureaucracy: on average, it takes 230 days for the MRC to approve a funding application. [_] Scientists carrying out basic research often have to spend significant amounts of time cleaning and organising data, while early-stage researchers face enormous obstacles to beginning careers. [_] Recommendation: The government should direct UK Resear
I was recently critical of The Lancet Group for a well-intentioned, but economically duff, editorial on drug pricing and innovation. If you want to avoid looking like the Lancet, check out Brian… | Jack Scannell LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any … your own smoke!” (Bob is definitely not a typical VC, incidentally; nor are his fund's returns; full disclosure: he's a Lumen investor) So to avoid 'breathing our own smoke', we use this tool at Lumen Bioscience to assess program financial viability—to hold ourselves to account. Fundamentally, we at Lumen Bio have cracked Eroom’s law; well, at least for targets amenable to our platform technology. The model is, in effect, our business model. The paper includes insights into h … your own smoke!” (Bob is definitely not a typical VC, incidentally; nor are his fund's returns; full disclosure: he's a Lumen investor) So to avoid 'breathing our own smoke', we use this tool at Lumen Bioscience to assess program financial viability—to hold ourselves to account. Fundamentally, we at Lumen Bio have cracked Eroom’s law; well, at least for targets amenable to our platform technology. The model is, in effect, our business model. The paper includes insights into h
Immortal Dragons Invests in Etheros for Age-Related Disease Therapies | TimePie posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, … owers 6mo Report this post Immortal Dragons , the $40M purpose-driven longevity fund, has announced a strategic investment in @Etheros — a biotech company developing a new class of therapeutics aimed at combating age-related diseases and potentially slowing human aging itself. Etheros is part of a new wave of European longevity biotechs—alongside Vandria, clock.bio , and Genflow Biosciences—pushing forward everything from mitophagy-based therapeutics and next-gen gene therapi … 1/2a clinical studies. The round was backed by XGEN Venture , a venture capital fund specializing in the life sciences sector, the British Business Bank, and a global biopharmaceutical company. The funding will support the first-in-human Phase 1/2a clinical trials to assess the safety and efficacy of the company’s lead gene therapy program, EPY201, in a broad population of patients with focal drug-resistant epilepsy (FRE). With future financing rounds, EpilepsyGTx also plans
Jack Scannell on drug R&D deci... – Cures & Capital – Apple Podcasts Sök Hem Nytt Topplistor Sök 21 januari 2025 1 tim 18 min Jack Scannell on drug R&D decision-making: The value of getting it right Cures & Capital Spela In this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more. If you're looking to deepen your understanding of these areas, there's no better guide than Jack. Jack brings a deep and holistic understanding of the biotech and pharma industry, having held a variety of roles—including being a neurosc
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Immortal Dragons Backs Etheros in Developing Catalytic Antioxidants for Aging-Linked Diseases - FinanceWire - Financial Press Release Distribution, Finance PR Toggle navigation Homepage Newsroom Pricing Blog About Us FAQs Contact Log in Immortal Dragons Backs Etheros in Developing Catalytic Antioxidants for Aging-Linked Diseases Posted by FinanceWire on December 9, 2025 | Featured Singapore, Singapore, December 9th, 2025, FinanceWire Immortal Dragons a $40 million longevity-focused innovation fund, has announced a strategic investment in Etheros, a research-oriented technology company developi … amental research technologies related to aging science. By backing Etheros, the fund seeks to enhance global understanding of oxidative stress mechanisms and contribute to the broader field of longevity-focused scientific research. “Immortal Dragons’ investment supports our continued focus on fundamental scientific development,” said Dr. Jack Scannell, CEO of Etheros. Boyang Wang, founder of Immortal Dragons, added: “Etheros is developing a platform that enables research into … bout Immortal Dragons Immortal Dragons is a purpose-driven longevity innovation fund headquartered in Singapore. The fund supports high-impact scientific and technological advances across aging research, with a portfolio of more than 15 companies. Immortal Dragons also promotes longevity education through book translations, a leading Chinese-language longevity podcast, public talks, and support for global scientific conferences. Comments are closed. About Us FinanceWire is a
#healthdata #desci #etheros #innovation #decentralizedscience #event | Natalia Sofia LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U
Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants English | 简体中文 | 繁體中文 | 한국어 | 日本語 Home | About us | Services | Partners | Events | Contact us | Login Saturday, June 27, 2026 Friday, 5 December 2025, 15:00 HKT/SGT Share: Source: Immortal Dragons Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants SINGAPORE, Dec 5, 2025 - (ACN Newswire) - Immortal Dragons , a forty million dollar purpose-driven longevity fund, has announced a strat … 85 discovery of the C60 carbon sphere, which was recognised with the 1996 Nobel Prize in Chemistry. While naturally occurring C60 is insoluble in water, Etheros has developed proprietary water-soluble derivatives for potential therapeutic applications. These compounds possess a chemistry that enables them to mimic the body’s endogenous antioxidant enzymes, particularly superoxide dismutase.Unlike conventional antioxidants, which are consumed during the neutralisation of … studies. About Immortal Dragons Immortal Dragons is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders’ talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants t
I would like to thank The Lancet Group whose dopey new editorial has given me a chance dig out a video I made on the typical errors that are applied to the analysis drug industry economics. | Jack Scannell LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time … to existing treatments? Only if it succeeds in all these stages can the company apply for approval. 🏛️ 4️⃣ Regulatory Review — The big decision All the data goes to national authorities (like the FDA, EMA). Experts carefully review everything — safety, effectiveness, quality. If satisfied, they finally say: ✅ Approved! 🏭 5️⃣ Manufacturing & Monitoring — Keeping it consistent Even after approval, every batch of medicine must be made under strict GMP rules and tested for … to existing treatments? Only if it succeeds in all these stages can the company apply for approval. 🏛️ 4️⃣ Regulatory Review — The big decision All the data goes to national authorities (like the FDA, EMA). Experts carefully review everything — safety, effectiveness, quality. If satisfied, they finally say: ✅ Approved! 🏭 5️⃣ Manufacturing & Monitoring — Keeping it consistent Even after approval, every batch of medicine must be made under strict GMP rules and tested for
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
false 2024 FY --12-31 0001919246 7955338 513443 7955338 513443 7955338 513443 96391 6103813 1.30 P10Y P10Y P9Y0M29D P10Y P9Y4M24D P8Y10M14D P9Y9M3D P10Y P9Y3M26D P9Y2M12D P2Y0M4D P4Y10M17D P4Y4M17D P4Y4M17D 0001919246 2024-01-01 2024-12-31 0001919246 2024-06-28 0001919246 2025-03-26 0001919246 2024-12-31 0001919246 2023-12-31 0001919246 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001919246 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001919246 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001919246 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001919246 2023-01-01 2023-12-31 0001919 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth compan … iSFN patients. Both of iSFN and EM are orphan indications for which we plan to apply for orphan drug designations. The orphan indication may decrease the scope of the ultimate development program that is necessary for approval and is associated with a marketing exclusivity period from the FDA along with some tax advantages.   Though the Phase 2a POC study design has not yet been completed, the study will take approximately twelve months after it is initiated. The primar … nical trials, as well as reduced FDA review periods and regulatory fees. We may apply for similar designations in additional jurisdictions, including India, Japan and Mexico, as well as additional regulatory classifications, such as FDA Breakthrough Therapy designation, that confer an advantage during development. As of the date of this Report, we have not submitted an application for orphan drug designation for CC8464.   5       CC8464, CT2000 and CT3000 … r CC8464 will expire in 2035. In addition, we have an additional pending patent application in India.   We have pending patent applications for each of CT2000 ophthalmic formulation and CT3000 injectable formulations, and for the treatment of pain.    Granted U.S. Patent 9,855,234 is directed to the diclofenac spray formulation and
RAGBRAI LIIl July 18-25, 2026 | 🚴♂️ Ride with purpose
Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Galle … /PRNewswire/ -- Immortal Dragons , the $40 million longevity-focused innovation fund, today announced its strategic investment in Etheros , a research-driven technology company developing proprietary water-soluble fullerene-based catalytic antioxidant materials . These advanced carbon nanostructure derivatives are designed for use in aging-related scientific research , particularly in the study of oxidative stress and its impact on biological systems. Growing Global Interest … f the C60 carbon sphere , a landmark achievement recognized with the 1996 Nobel Prize in Chemistry . While traditional C60 is insoluble in water, Etheros has created proprietary water-soluble fullerene derivatives for laboratory and research applications. These specialized materials are engineered to function as catalytic antioxidants , meaning they can continuously convert ROS into more stable molecules without being consumed in the process. This mechanism, known as catalyti … hat expand global understanding of aging mechanisms. By supporting Etheros, the fund aims to strengthen research into oxidative stress, advanced materials chemistry, and catalytic antioxidant systems . "Immortal Dragons are both bold and thoughtful—their support has been invaluable as we advance our scientific platform," said Dr. Jack Scannell , CEO of Etheros.Founder of Immortal Dragons, Boyang Wang , added: "Etheros represents a distinctive approach to aging science, ground … bout Immortal Dragons Immortal Dragons is a purpose-driven longevity innovation fund headquartered in Singapore. The fund supports high-impact scientific and technological advances across aging research, with a portfolio of more than 15 companies. Immortal Dragons also promotes longevity education through book translations, a leading Chinese-lang
Etheros HealthData Foundation is transforming global health data management | Global Health Connector Skip to content About Us Who we are Our Journey so Far Ambassadors Ecosystems Thematic Ecosystems Geographic Ecosystems Connector Programme Services Digital Health Innovation Updates News & Insight Events Join as a member News 20 November 2024 Etheros HealthData Foundation is transforming global health data management Search ... Results See all results News Etheros HealthData Foundation is transforming global health data management Published on: 20 November 2024 Member News Partnerships a
Landmark Report Charts Rise of Decentralized AI as Critical Pillar for Equitable Healthcare Systems LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Emulate Publishes Landmark Study Validating Organ-on-a-Chip Technology for Predictive Toxicology in Preclinical Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Emulate Publishes Landmark Study Validating Organ-on-a-Chip Technology for Predictive Toxicology in Preclinical Development December 6, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Emulate, Inc. today announced the publication of a landmark study, “Performance assessment and economic analysis of a hu … ed Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology is assisting researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter . View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005345/en/ Contacts Me … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica … LinkedIn Share to Reddit Key Insights Immortal Dragons, a $40 million longevity fund, has made a strategic investment in Etheros Pharmaceuticals, which is developing water-soluble fullerene derivatives as catalytic antioxidants to combat aging-related diseases. Etheros' lead compound demonstrated a 14% median lifespan extension in middle-aged mice and showed normalizing effects on behavior and neuroinflammation in an Alzheimer's disease mouse model. The company' … cond. Immortal Dragons Search company , a Singapore-based $40 million longevity fund, has announced a strategic investment in Etheros Pharmaceuticals Search company , a Nashville-based biotechnology company developing a novel class of catalytic antioxidants targeting age-related diseases. The investment supports Etheros' advancement of water-soluble fullerene derivatives designed to neutralize oxidative stress, a fundamental mechanism implicated in cellular damage and ag … 85 discovery of the C60 carbon sphere, which was recognized with the 1996 Nobel Prize in Chemistry. While naturally occurring C60 is insoluble in water, Etheros has developed proprietary water-soluble derivatives for therapeutic applications. These compounds possess chemistry that enables them to mimic the body's endogenous antioxidant enzymes, particularly superoxide dismutase. Unlike conventional antioxidants that are consumed during the neutralization of reactive oxyg
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
VDP-74 [Assessment]: Etheros Pharma - Jack Scannell - Passed Proposals - Governance Forum | VitaDAO = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-reactions_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="3" data-theme-name="sam's simple theme"/> Governance Forum | VitaDAO VDP-74 [Assessment]: Etheros Pharma - Jack Scannell Proposals Passed Proposals longevion January 3, 2023, 5:05p … ds mammalian lifespan and neural healthspan (based on fullerene chemistry) This proposal is based on the supporting documents provided by Etheros Pharma, as well as questions and answers to their team, and senior reviews. If this goes on-chain, the VITA token holders will ratify the WG’s assessment via a decentralized vote Applicant (project lead): Dr. Jack Scannell Simple Summary Etheros is pioneering a new class of small molecule drugs, based on Nobel Prize-winning fulleren … the therapeutic concept, before raising the large sums of capital necessary to fund trials in common diseases. Intellectual Property The bulk of the current raise will be invested to secure patent protection for new chemical technologies so we do not want to disclose any detail at this stage. Note that the Etheros has engaged experienced IP counsel and that the team has deep experience in IP creation. We are confident that we will secure robust IP. We are also confident that … can progress a collaboration with a philanthropic organisation that intends to fund preclinical studies in what could become a large and lucrative indication. With a stock of C3, plus our existing contacts, we may be able to create similar opportunities in other indications that match our priorities. We also want some stock in hand to start the major preclinical development effort after our next raise. $200k to synthesise, purify, quality-test, and assay a range of novel che … ing-related diseases. The technology was built on ~$40m of competitive academic grant funding. Professor Sir Marc Feldmann : An immunologist who Invented and developed the first successful monoclonal antibody therapy, anti-TNF, in his pioneering work with Remicade in the early 1990s. Remicade went on to sell over $7bn per year and the anti-TNFs b